Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 20, 2012

La Jolla Pharmaceutical Picks Up Solana’s Galectin-3 Antagonist

  • La Jolla Pharmaceutical acquired global development and commercialization rights to Solana Therapeutics’ inhibitor of galectin-3, GCS-100. Galectin-3 has been implicated in cancer and chronic organ failure.

    GCS-100's ongoing development as an anticancer and antifibrotic agent is supported by preclinical and clinical investigation including Phase I and Phase II trials involving more than 140 patients. Experimental results to date indicate that GCS-100 specifically inhibits galectin-3 in immune cells and confers anticancer activity in several tumor types.

    Galectin-3 plays a key role in the immune system's response to cancer and tissue injury. Investigators at the Ludwig Cancer Institute have reportedly shown that galectin-3 inhibits the activity of cancer-killing T cells and that pharmacologically blocking galectin-3 with GCS-100 reactivates these T cells. In addition, a number of other academic studies have concluded that galectin-3 is a mediator of fibrosis after heart, kidney, lung, and liver injury.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »